Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company advancing novel solutions in immunology and oncology, today announced the appointment of Vincent LoPriore, Founder of Gravitas ...

With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under ...

Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling ...

Tony turns his attention to pivotal phase 3 trials and what mix of make or break biotechs you should have in your portfolio.

Iovance's Amtagvi is the first TIL therapy approved by the U.S. Food and Drug Administration (FDA). Its first approved indication is for advanced melanoma. Amtagvi is off to a great start after its ...

TD Cowen downgraded Medpace (MEDP) to Hold from Buy with a price target of $328, down from $370. The firm cites the challenging biotech funding ...

The sector is defensive, and biopharmaceuticals have, for the most part, limited tariff and transfer price exposure, he ...

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...

The market turbulence unleashed by President Donald Trump’s tariff policies will likely evaporate the trickle of biotech IPOs ...

Find out what makes Basel's biotech hub so successful, as it has cemented its place as one of Europe's brightest life ...

Political pressure and persistently high interest rates have some wondering if the industry’s model is broken.